XML 153 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Parent-Only Financial Statements (Tables) - Parent [Member]
12 Months Ended
Dec. 31, 2024
Parent-Only Financial Statements (Tables) [Line Items]  
Schedule of Condensed Balance Sheets

The following represents condensed financial information of the parent company:

 

As of December 31,

   

2023

 

2024

   

RMB

 

RMB

 

US$

ASSETS/(LIABILITIES)

   

 

   

 

   

 

Cash and cash equivalents

 

1,205,993

 

 

2,227,649

 

 

309,895

 

Prepayments

 

13,776

 

 

891

 

 

124

 

Due from intercompany

 

456,041,568

 

 

814,547,651

 

 

113,314,180

 

Investment in subsidiaries

 

(471,994,335

)

 

(585,987,070

)

 

(81,518,429

)

TOTAL ASSETS (LIABILITIES)

 

(14,732,998

)

 

230,789,121

 

 

32,105,770

 

SHAREHOLDERS’ EQUITY (DEFICIT)

   

 

   

 

   

 

Shareholders’ equity (deficit):

   

 

   

 

   

 

Class A ordinary shares ($0.002 par value; 12,141,093 and 14,141,093 shares authorized as of December 31, 2023 and 2024, respectively; 4,192,730 and 13,273,596 shares issued as of December 31, 2023 and 2024, respectively; 3,724,236 and 12,815,143 shares outstanding as of December 31, 2023 and 2024, respectively)*

 

50,106

 

 

176,842

 

 

24,601

 

Class B ordinary shares ($0.002 par value; 2,858,909 shares authorized; 2,858,909 shares issued and outstanding as of December 31, 2023 and 2024)*

 

36,894

 

 

36,894

 

 

5,132

 

Additional paid-in capital

 

428,310,028

 

 

780,499,664

 

 

108,577,662

 

Accumulated deficit

 

(452,031,693

)

 

(565,218,741

)

 

(78,629,283

)

Statutory reserves

 

6,647,109

 

 

6,647,109

 

 

924,699

 

Accumulated other comprehensive income

 

2,254,558

 

 

8,647,353

 

 

1,202,959

 

TOTAL NANO LABS LTD SHAREHOLDERS’ EQUITY (DEFICIT)

 

(14,732,998

)

 

230,789,121

 

 

32,105,770

 

*        After giving effect of the reverse stock splits, see Note 12.

Schedule of Condensed Statements of Operations and Comprehensive Income (Loss)
 

For the years ended December 31,

   

2022

 

2023

 

2024

   

RMB

 

RMB

 

RMB

 

US$

Net revenues

 

 

 

 

 

 

 

 

Operating expenses:

   

 

   

 

   

 

   

 

Selling and marketing expenses

 

 

 

 

 

 

 

 

General and administrative expenses

 

5,822,906

 

 

471,664

 

 

683,178

 

 

95,039

 

Total operating expenses

 

5,822,906

 

 

471,664

 

 

683,178

 

 

95,039

 

Loss from operations

 

(5,822,906

)

 

(471,664

)

 

(683,178

)

 

(95,039

)

Finance income (expense)

 

66,144

 

 

110,971

 

 

(13,140

)

 

(1,828

)

Investment income

 

53,809

 

 

 

 

 

 

 

Income (loss) from investment in subsidiaries

 

36,821,839

 

 

(252,463,079

)

 

(112,490,730

)

 

(15,648,925

)

Net income (loss) attributable to Nano Labs Ltd

 

31,118,886

 

 

(252,823,772

)

 

(113,187,048

)

 

(15,745,792

)

Comprehensive income (loss):

   

 

   

 

   

 

   

 

Net income (loss)

 

31,118,886

 

 

(252,823,772

)

 

(113,187,048

)

 

(15,745,792

)

Other comprehensive income (loss)

   

 

   

 

   

 

   

 

Foreign currency translation adjustment

 

4,566,656

 

 

155,229

 

 

6,392,795

 

 

889,320

 

Total comprehensive income (loss) attributable to Nano Labs Ltd

 

35,685,542

 

 

(252,668,543

)

 

(106,794,253

)

 

(14,856,472

)

Schedule of Condensed Statements of Cash Flows
 

For the years ended December 31,

   

2022

 

2023

 

2024

   

RMB

 

RMB

 

RMB

 

US$

Net cash provided by (used in) operating activities

 

3,911,561

 

 

344,012

 

 

(281,829

)

 

(39,206

)

Net cash used in investing activities

 

(155,900,936

)

 

(68,918,960

)

 

(312,142,434

)

 

(43,423,075

)

Net cash provided by financing activities

 

144,043,186

 

 

72,802,734

 

 

315,620,394

 

 

43,906,905

 

Effect of exchange rate changes on cash and cash equivalents

 

7,883,387

 

 

(3,047,562

)

 

(2,174,475

)

 

(302,498

)

Net increase (decrease) in cash and cash equivalents

 

(62,802

)

 

1,180,224

 

 

1,021,656

 

 

142,126

 

Cash and cash equivalents at beginning of the year

 

88,571

 

 

25,769

 

 

1,205,993

 

 

167,769

 

Cash and cash equivalents at end of the year

 

25,769

 

 

1,205,993

 

 

2,227,649

 

 

309,895